Zevra therapeutics provides fda update on the pdufa action date for arimoclomol as a treatment for niemann-pick disease type c

The new prescription drug user fee act (pdufa) action date set by the fda is september 21, 2024 celebration, fla., march 04, 2024 (globe newswire) -- zevra therapeutics, inc. (nasdaqgs: zvra) (zevra or the company), a rare disease therapeutics company, today announced the u.s. food and drug administration (fda) has extended the review period for the new drug application (nda) for arimoclomol, an investigational orally delivered, first-in-class treatment for niemann-pick disease type c (npc).
ZVRA Ratings Summary
ZVRA Quant Ranking